Recently the World Malaria report reviewed 20 years of malaria response. Since 2000, 7.6 million lives have been saved globally and 1.5 billion Malaria cases averted.
In these last two decades European Vaccine Initiative (EVI) has supported a diverse and extensive portfolio of Malaria Vaccine candidates. The most advanced Malaria vaccine candidate, supported by EVI, is R21/Matrix M, a pre-erythrocytic vaccine candidate that is currently undergoing phase II clinical trial and is in preparation for phase III clinical testing. As progress to #EndMalaria continues to plateau particularly in high burden countries, we remain deeply committed to developing a vaccine that would have significant impact on Malaria control.
Full Report by the World Health Organization (WHO): https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2020